Targeting chelatable iron as a therapeutic modality in Parkinson's disease

D Devos, C Moreau, JC Devedjian, J Kluza… - Antioxidants & redox …, 2014 - liebertpub.com
Aims: The pathophysiological role of iron in Parkinson's disease (PD) was assessed by a
chelation strategy aimed at reducing oxidative damage associated with regional iron …
被引用次数：608 相关文章
[HTML] nih.gov

[HTML][HTML] Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease

D Devos, C Moreau, JC Devedjian, J Kluza… - Antioxidants & Redox …, 2014 - ncbi.nlm.nih.gov
Aims: The pathophysiological role of iron in Parkinson's disease (PD) was assessed by a
chelation strategy aimed at reducing oxidative damage associated with regional iron …

[引用][C] Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease

D Devos, C Moreau, JC Devedjian, J Kluza… - Antioxidants & Redox …, 2014 - cir.nii.ac.jp
Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease | CiNii Research
CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …

Targeting chelatable iron as a therapeutic modality in Parkinson's disease

D Devos, C Moreau, JC Devedjian, J Kluza, M Petrault… - 2014 - pubmed.ncbi.nlm.nih.gov
Aims The pathophysiological role of iron in Parkinson's disease (PD) was assessed by a
chelation strategy aimed at reducing oxidative damage associated with regional iron …

Targeting chelatable iron as a therapeutic modality in Parkinson's disease

D Devos, D Pöltl, M Leist - 2014 - kops.uni-konstanz.de
Aims: The pathophysiological role of iron in Parkinson's disease (PD) was assessed by a
chelation strategy aimed at reducing oxidative damage associated with regional iron …

Targeting chelatable iron as a therapeutic modality in Parkinson's disease.

D Devos, C Moreau, JC Devedjian, J Kluza… - Antioxidants & Redox …, 2014 - europepmc.org
Aims The pathophysiological role of iron in Parkinson's disease (PD) was assessed by a
chelation strategy aimed at reducing oxidative damage associated with regional iron …

Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease

D Devos, C Moreau, JC Devedjian, J Kluza… - Antioxidants & Redox …, 2014 - hero.epa.gov
Aims: The pathophysiological role of iron in Parkinson's disease (PD) was assessed by a
chelation strategy aimed at reducing oxidative damage associated with regional iron …

Targeting chelatable iron as a therapeutic modality in Parkinson's disease.

D Devos, C Moreau, JC Devedjian, J Kluza… - Antioxidants & Redox …, 2014 - europepmc.org
Aims The pathophysiological role of iron in Parkinson's disease (PD) was assessed by a
chelation strategy aimed at reducing oxidative damage associated with regional iron …

Targeting chelatable iron as a therapeutic modality in Parkinson's disease

D Devos, D Pöltl, M Leist - 2014 - kops.uni-konstanz.de
Aims: The pathophysiological role of iron in Parkinson's disease (PD) was assessed by a
chelation strategy aimed at reducing oxidative damage associated with regional iron …